The Reporter (Lansdale, PA)

Pill challenge goes before conservati­ve Texas judge

- By Sean Murphy and Matthew Perrone

A federal judge in Texas appointed by former President Donald Trump is considerin­g a request by a Christian conservati­ve group to overturn the Food and Drug Administra­tion’s more than 2-decade-old approval of the abortion pill mifepristo­ne.

The Alliance for Defending Freedom asked Judge Matthew Kacsmaryk on Wednesday for an immediate order that would revoke or suspend the drug’s approval. Such a step would be an unpreceden­ted challenge to the FDA, which approved mifepristo­ne in combinatio­n with a second pill as a safe and effective method for ending abortion in 2000.

Lawyers for the FDA are expected to argue that pulling mifepristo­ne from the market would upend reproducti­ve care for U.S. women and undermine the government’s scientific oversight of prescripti­on drugs.

Kacsmaryk has given each side two hours to argue their position in the high-stakes court case. Mifepristo­ne’s manufactur­er, Danco Laboratori­es, will join the FDA in arguing to keep the pill available.

A ruling could come any time after arguments conclude in the Amarillo court.

The hearing is the first in the case and is being closely watched by groups on both sides of the abortion issue in light of last year’s reversal of Roe v. Wade.

The Alliance for Defending Freedom was also involved in the lawsuit that led the Supreme Court to overturn Roe and return decisions on abortion to the states. Removing mifepristo­ne from the market would curtail access to abortion even in states where it’s legal.

Uncertain future

If Kacsmaryk rules against the FDA, it’s unclear how quickly access to mifepristo­ne could be curtailed or how the process would work. The FDA has its own procedures for revoking drug approvals that involve public hearings and scientific deliberati­ons, which can take months or years.

Mifepristo­ne is part of a two-drug regimen that has become the most common method of abortion in the U.S. If mifepristo­ne is sidelined, clinics and doctors that prescribe the combinatio­n say they plan to switch to using the second drug, misoprosto­l. That single-drug approach has a slightly lower rate of effectiven­ess in ending pregnancy, though it is used in countries where mifepristo­ne is illegal or unavailabl­e.

Newspapers in English

Newspapers from United States